The signing ceremony for strategic cooperation between Shanghai Reunion Biotechnology Co., Ltd. (hereafter referred to as “Reunion”) and Tigermed-Jyton was held successfully on December 15 in Shanghai. Mr. Peng Yifei, General Manager of Tigermed-Jyton, Ms. Yang Yifei, Overseas Affairs Director of Tigermed-Jyton, Mr. Pan Zhen, Founder and Chairman of Reunion, and Mr. Chen Liang, Deputy General Manager of Reunion, etc. attended the signing ceremony.
Reunion has dedicated to R&D and industrial transformation of the medical hydrogel for years. Tigermed-Jyton and Reunion will develop strategic cooperation in its application in tumor radiotherapy protection, wound repair, tumor embolization, etc., make full use of their advantages and achieve a win-win situation. As a China leading CRO company in regulatory affairs and clinical research of medical devices, Tigermed-Jyton aims to reduce the registration risk, shorten the project cycle, save R&D expenditure and promote the process of product marketization for clients with professional service capabilities. In this strategic cooperation, Tigermed-Jyton will provide all-round services for Reunion, including the medical device system, registration, clinical trials and overseas registration.
(▲ From left to right: Mr. Peng Yifei, General Manager of Tigermed-Jyton, Ms. Yang Yifei, Overseas Affairs Director of Tigermed-Jyton, Mr. Chen Liang, Deputy General Manager of Reunion, Mr. Pan Zhen, Founder and Chairman of Reunion)
Mr. Peng Yifei, General Manager of Tigermed-Jyton, said, “As an innovative enterprise focusing on medical hydrogels, Reunion is committed to providing systematic solutions such as tumor radiotherapy protection, tumor embolization and wound repair. Reunion and Tigermed-Jyton share the common goal of benefiting human health. I am very happy for the successful building of strategic cooperative ties. In the future, Tigermed-Jyton and Reunion will further develop in-depth exchanges and cooperation, and work hand in hand for common development and for providing better medical device products and services for patients and the public.”
Mr. Pan Zhen, Chairman of Reunion, said, “Tigermed-Jyton is an industry-leading CRO enterprise in regulatory affairs and clinical research. Supported by strong capabilities to provide clinical research services and a global service network, Tigermed-Jyton can provide comprehensive solutions for clinical research of innovative devices. I’m glad we have successfully reached a strategic cooperation to jointly satisfy the health needs of patients. I believe that this strategic cooperation will further accelerate the approval and launching of series products developed by Reunion, so that patients in China and even in the world can benefit from more innovative medical devices earlier.”